In high-purity TCGA melanoma samples, BRAF mutations were not associated with MCS (Supplementary Fig. 5); thus, we cannot exclude a potential selective advantage for BRAF mutated MEL samples when grown in vitro. This evidence concerns the gene BRAF and melanoma.